|
Commitment of Novartis in advancing treatments for patients with cancer and rare diseases
|
02 December 2010 |
|
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
|
18 November 2010 |
|
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate
|
04 November 2010 |
|
Novartis drug Afinitor® approved by FDA
|
31 October 2010 |
|
Novartis delivers excellent performance in third quarter
|
22 October 2010 |
|
Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis
|
19 October 2010 |
|
Novartis affirms commitment to sustain efforts toward final elimination of leprosy
|
13 October 2010 |
|
Novartis discontinues development of two investigational compounds
|
06 October 2010 |
|
Novartis sells US rights to the overactive bladder treatment Enablex®
|
28 September 2010 |
|
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment
|
23 September 2010 |